Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (141-150 of 246) with videos related to

Pageof 25
Sort By:
Journal of Clinical Medicine|July 14, 2023
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib ExperiencePeter C Taylor, Cedric Laedermann, Rieke Alten, et al.
Trials|June 6, 2019
Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementationClifton O Bingham, Carol L Gaich, Amy M DeLozier, et al.
The Journal of Rheumatology|February 17, 2017
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation <i>in Vitro</i>Louisa Jeffery, Helena L Fisk, Philip C Calder, et al.
Annals of the Rheumatic Diseases|February 28, 2018
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 studyPeter C Taylor, Michael H Schiff, Qingmin Wang, et al.
Journal of Autoimmunity|August 8, 2024
Inflammatory disease status and response to TNF blockade are associated with mechanisms of endotoxin toleranceFelix Il Clanchy, Federica Borghese, Jonas Bystrom, et al.
RMD Open|March 10, 2022
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapyPeter C Taylor, Rieke Alten, Jose María Álvaro Gracia, et al.
Journal of Autoimmunity|March 4, 2022
Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expressionFelix I L Clanchy, Federica Borghese, Jonas Bystrom, et al.
Rheumatology (Oxford, England)|January 23, 2024
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term studyRoberto Caporali, Peter C Taylor, Daniel Aletaha, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|November 17, 2020
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term studyJosef S Smolen, Li Xie, Bochao Jia, et al.
Pageof 25

Showing results (141-150 of 246) with videos related to

Sort By:
Pageof 25
Journal of Clinical Medicine|July 14, 2023
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib ExperiencePeter C Taylor, Cedric Laedermann, Rieke Alten, et al.
Trials|June 6, 2019
Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementationClifton O Bingham, Carol L Gaich, Amy M DeLozier, et al.
The Journal of Rheumatology|February 17, 2017
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation <i>in Vitro</i>Louisa Jeffery, Helena L Fisk, Philip C Calder, et al.
Annals of the Rheumatic Diseases|February 28, 2018
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 studyPeter C Taylor, Michael H Schiff, Qingmin Wang, et al.
Journal of Autoimmunity|August 8, 2024
Inflammatory disease status and response to TNF blockade are associated with mechanisms of endotoxin toleranceFelix Il Clanchy, Federica Borghese, Jonas Bystrom, et al.
RMD Open|March 10, 2022
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapyPeter C Taylor, Rieke Alten, Jose María Álvaro Gracia, et al.
Journal of Autoimmunity|March 4, 2022
Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expressionFelix I L Clanchy, Federica Borghese, Jonas Bystrom, et al.
Rheumatology (Oxford, England)|January 23, 2024
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term studyRoberto Caporali, Peter C Taylor, Daniel Aletaha, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|November 17, 2020
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term studyJosef S Smolen, Li Xie, Bochao Jia, et al.
Pageof 25